-
Mashup Score: 5FDA grants accelerated approval to pirtobrutinib - 6 day(s) ago
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor.
Source: www.fda.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Digital Equity in Hematology-Oncology Fellowship Websites: Toward Standardization, Quality, and Transparency - 30 day(s) ago
Improving trainee program websites may help applicants and programs in the era of virtual interviews
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
π» Increased standardization, quality & transparency in #hemonc fellowship websites would allow applicants to better assess their level of interest in training at a particular program or its fit for them as individuals before applying. π https://t.co/4ZebLfgxpq @richgodby https://t.co/2VTwlG1TN7
-
-
Mashup Score: 4Digital Equity in Hematology-Oncology Fellowship Websites: Toward Standardization, Quality, and Transparency - 1 month(s) ago
Improving trainee program websites may help applicants and programs in the era of virtual interviews
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
π» Increased standardization, quality & transparency in #hemonc fellowship websites would allow applicants to better assess their level of interest in training at a particular program or its fit for them as individuals before applying. π https://t.co/4ZebLfgxpq @richgodby https://t.co/2VTwlG1TN7
-
-
Mashup Score: 0Optimizing initial therapy of CLL - 2 month(s) ago
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the specific considerations for optimizing chronic lymphocytic leukemia (CLL) treatment in patients in the frontline setting. These include age, comorbidities, length of treatment (time-limited or continuous), and access to lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Non-Malignant Blood Disorders | VJHemOnc - 2 month(s) ago
Explore the latest updates and expert interviews in non-malignant blood disorders on The Non-Malignant Channel by VJHemOnc
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
You may have noticed our logo has changed... ππ©Έ We now have a Non-Malignant Channel! We are committed to providing you with comprehensive insights into #blooddisorders, from #cancers to #nonmalignant conditions π¬ π https://t.co/DCGCNNnXP8 Our regular #HemOnc content willβ¦ https://t.co/zZS7eLlMsS https://t.co/HvYGWi1s0S
-
-
Mashup Score: 0MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 2 month(s) ago
Skip to content Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional. Visit …
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Clinical guidance for the use of bispecific antibodies in NHL - 2 month(s) ago
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Socioeconomic and racial disparities in myeloma trial recruitment - 2 month(s) ago
Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, discusses how socioeconomic and racial inequalities persist during the enrollment process in multiple myeloma clinical trials. Patients from a lower socioeconomic background are underrepresented in clinical trials, and will have worse overall survival, even after receiving treatment. Gaps in outcomes are additionally more pronounced in older patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0iwCLL 2023 | VJHemOnc - 2 month(s) ago
The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
This is an important @US_FDA approval for Chronic Lymphocytic Leukemia patients who have received prior Tx. Iβll be discussing this with @tobyeyre82 on a future #HemOnc Pulse podcast. Stay tuned. https://t.co/MMHnJYJjHu